Differential binding of biofilm-derived and suspension-grown Staphylococcus aureus to immobilized platelets in shear flow

Journal of Infectious Diseases

Volumn 199, Issue 5, 2009, Pages 633-640

  George, Niraj Procopio Evagrio ^a   Ymele Leki, Patrick ^a   Konstantopoulos, Konstantinos ^b   Ross, Julia Myers ^a  

^a Baltimore County   (United States)

^b Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; PLASMA PROTEIN; PROTEIN CLUMPING FACTOR A; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BACTERIAL GROWTH; BIOFILM; BLOOD VESSEL WALL; CELL ADHESION; CELL CULTURE; CELL POPULATION; CONTROLLED STUDY; IMMOBILIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHEAR FLOW; SHEAR STRESS; STAPHYLOCOCCUS AUREUS; THROMBOCYTE;

BACTERIAL ADHESION; BIOFILMS; BLOOD PLATELETS; BLOOD PROTEINS; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; PLASMA; SHEAR STRENGTH; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 61849179602     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/596316     Document Type: Article

References (32)

1. Pace JL, Rupp ME, Finch RG. Biofilms, infection and antimicrobial therapy. Boca Raton, FL: Taylor and Francis Group, 2006.
2. Beenken KE, Dunman PM, McAleese FM, et al. Global gene expression in Staphylococcus aureus biofilms. J Bacteriol 2004; 186:4665-84.
3. Yarwood JM, Bartels DJ, Volper EM, Greenberg EP. Quorum sensing in Staphylococcus aureus biofilms. J Bacteriol 2004; 186:1838-50.
4. Wu JA, Kusuma C, Mond JJ, Kokai-kun JF. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother 2003; 47:3407-14.
5. Brady RA, Leid JG, Camper AK, Costerton JW, Shirtliff ME. Identification of Staphylococcus aureus proteins recognized by the antibody-mediated immune response to a biofilm infection. Infect Immun 2006; 74:3415-26.
6. Fux CA, Wilson S, Stoodley P. Detachment characteristics and oxacillin resistance of Staphylococcus aureus biofilm emboli in an in vitro catheter infection model. J Bacteriol 2004; 186:4486-91.
7. Heilmann C, Niemann S, Sinha B, Herrmann M, Kehre BE, Peters G. Staphylococcus aureus fibronectin-binding protein (FnBP)-mediated adherence to platelets, and aggregation of platelets induced by FnBPA but not by FnBPB. J Infect Dis 2004; 190:321-9.
8. Fitzgerald JR, Loughman A, Keane A, et al. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgRIIa receptor. Mol Microbiol 2006; 59:212-30.
9. Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol 2006; 4:445-57.
10. George NPE, Wei Q, Shin PK, Konstantopoulos K, Ross JM. Staphylococcus aureus adhesion via Spa, ClfA and SdrCDE to immobilized platelets demonstrates shear dependent behavior. Arterioscler Thromb Vasc Biol 2006; 26:2394-400.
11. George NPE, Konstantopoulos K, Ross J. Differential kinetics and molecular recognition mechanisms involved in early versus late growth phase Staphylococcus aureus cell binding to platelet layers under physiological shear conditions. J Infect Dis 2007; 196:639-46.
12. Ymele-Leki P, Ross JM. Erosion from Staphylococcus aureus biofilms grown under physiologically relevant fluid shear forces yields bacterial cells with reduced avidity to collagen. Appl Environ Microbiol 2007; 73:1834-41.
13. Domanski PJ, Patel PR, Bayer AS, et al. Characterization of humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus. Infect Immun 2005; 73:5229-32.
14. Patti JM, Bremell T, Peitrasik DK, et al. The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis. Infect Immun 1994; 62:152-61.
15. Mascari L, Ross JM. Quantifying the temporal expression of the Staphylococcus aureus collagen adhesin. Microb Pathog 2002; 32:99-103.
16. Mohamed N, Livia V, Speziale P, Ross J. Quantification of Staphylococcus aureus cell surface adhesins using flow cytometry. Microb Pathog 2000; 29:357-61.
17. Mohamed N, Rainier TRJ, Ross JM. Novel experimental study of receptor-mediated bacterial adhesion under the influence of fluid shear. Biotechnol Bioeng 2000; 68:628-36.
18. Mascari L, Ross JM. Hydrodynamic shear and collagen receptor density determine the adhesion capacity of S. aureus to collagen. Ann Biomed Eng 2001; 29:956-62.
19. Mascari L, Ymele-Leki P, Eggleton CD, Speziale P, Ross JM. Fluid shear contributions to bacteria cell detachment initiated by a monoclonal antibody. Biotechnol Bioeng 2003; 83:65-74.
20. Giacometti A, Cirioni O, Gov Y, et al. RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1979-83.
21. Callegan MC, Engel LS, Hill JM, O'Callaghan RJ. Corneal virulence of Staphylococcus aureus: roles of alpha-toxin and protein A in pathogenesis. Infect Immun 1994; 62:2478-82.
22. Rupp CJ, Fux CA, Stoodley P. Viscoelasticity of Staphylococcus aureus biofilms in response to fluid shear allows resistance to detachment and facilitates rolling migration. Appl Environ Microbiol 2005; 71:2175-8.
23. Stoodley P, Sauer K, Davies DG, Costerton JW. Biofilms as complex differentiated communities. Annu Rev Biochem 2002; 56:187-202.
24. Lesens O, Hansmann Y, Brannigan E, et al. Positive surveillance blood culture is a predictive factor for outcomes in patients with Staphylococcus aureus bacteremia. J Infect Dis 2004; 48:245-52.
25. Heilmann C, Herrmann M, Kehrel BE, Peters G. Platelet-binding domains in 2 fibrinogen-binding proteins of Staphylococcus aureus identified by phage display. J Infect Dis 2002; 186:32-9.
26. Siboo IR, Chambers HF, Sullam PM. Role of SraP, a serine-rich surface protein of Staphylococcus aureus, in binding to human platelets. Infect Immun 2005; 73:2273-80.
27. Nguyen T, Ghebrehiwet B, Peerschke EIB. Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for Staphylococcal interactions with platelets. Infect Immun 2000; 68:2061-8.
28. Loughman A, Fitzgerald JR, Brennan MP, et al. Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol Microbiol 2005; 57:804-18.
29. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 2001; 184:1572-80.
30. Reilly S, Wenzel E, Reynolds L, Bennett B, Patti J, Hetherington S. Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Antimicrob Agents Chemother 2005; 49:959-62.
31. Weems JJ Jr, Steinberg JP, Filler S, et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50:2751-5.
32. Becker P, Hufnagle W, Peters G, Herrmann M. Detection of differential gene expression in biofilm-forming versus planktonic populations of Staphylococcus aureus using micro-representational-difference analysis. Appl Environ Microbiol 2001; 67:2958-65.